WARRANTS OF SERIES TO6
PROSTATYPE GENOMICS AB

EXERCISE PERIOD: 1-15 SEPTEMBER 2026

IMPORTANT INFORMATION
This information document has been prepared by Prostatype Genomics AB ("Prostatype Genomics" or the "Company"). Readers are advised to read the information memorandum published by Prostatype Genomics AB in July 2026 in connection with the Company's rights issue of units, which describes the risks associated with an investment in the Company. The information memorandum is available for download on the Company's website (www.prostatypegenomics.com).

NAVIA
CORPORATE FINANCE

BIRCHTREE ADVISORY

CEO FREDRIK RICKMAN BEGINS

Prostate cancer is the most common form of cancer among men in Europe and one of the major cancer challenges globally. Despite significant medical advances, selecting the right treatment remains complex. Being able to distinguish patients who require active treatment from those who can avoid or defer treatment is crucial – both for patients' quality of life and for more efficient use of healthcare resources. It is within this challenge that Prostatype Genomics has its foundation.

Following more than 15 years of research at Karolinska Institutet, Prostatype® was developed – a patented and IVDR-approved prognostic genetic test that combines molecular biomarkers with AI-based analysis. By analyzing existing biopsy material, the test can provide physicians with additional information about the aggressiveness of the disease and thereby support more individualized treatment decisions, without the patient having to undergo a new procedure.

We are now entering an important phase in which our focus is increasingly on commercial establishment and scalability. Prostatype® is commercially available in selected markets in EMEA, while we continue to build clinical acceptance through local validation activities. Our strategically most important focus is the United States, where the test was commercially launched in 2024. Here, we are continuing our work on the Medicare process, which we believe could have a significant impact on future market penetration and reimbursement for Prostatype®.

With a fully developed product, a scalable business model and significant market potential, we are entering a period with several important value-creating opportunities. Following the fully subscribed rights issue in July, the Company's financial position has been strengthened. The exercise of TO6 could further strengthen our financial flexibility and create conditions for continued commercialization, market expansion and our ongoing Medicare efforts at a rapid pace.

We see significant potential for Prostatype® to become an established part of the more personalized prostate cancer care of the future. With the support of our shareholders, we can continue our efforts to translate the research and product development built up over many years into commercial and clinical value. I remain highly confident about the journey ahead.

Fredrik Rickman – CEO of Prostatype Genomics AB

INVESTMENT HIGHLIGHTS

Positioned for commercial breakthrough in the USA – Over the past several years, Prostatype Genomics has invested in and built the regulatory and commercial foundation for a broad launch of Prostatype® in the United States. The Company has established laboratory and billing partners and ongoing discussions regarding further commercial scaling.

Ongoing Medicare process with significant commercial potential – the Company is in an advanced and constructive process for reimbursement from Medicare in the USA. The application has been submitted within an existing regulatory framework with an established reimbursement rate of USD 3,783 per completed test, creating the potential for attractive future revenues.

Large and growing addressable market – the USA is the largest market in the world for prognostic biomarkers within prostate cancer. Unlike in many European markets, biomarkers of this type are included in U.S. national clinical guidelines, explaining the broad clinical adoption.

Clear clinical need and strong patient benefits – Prostatype® addresses a significant medical challenge, as many patients today are overtreated with surgery or radiation therapy despite having a low risk of fatal disease. The test supports more precise treatment decisions and may reduce the risk of serious lifelong side effects such as erectile dysfunction and incontinence.

Short path to revenue generation – Prostatype® is already being used at selected hospitals in the United States. With the regulatory and commercial infrastructure in place, the Company believes that the time from Medicare approval to broader commercialization and scalable revenue generation will be relatively short.

Clear value-driving milestones – The ongoing Medicare process represents a key value driver for the Company. Approval for reimbursement is expected to enable accelerated commercialization and broader market penetration in the United States.

Prostatype Genomics

PROSTATYPE GENOMICS

Prostatype Genomics is built on more than 15 years of research into the genetic mechanisms of prostate cancer. The Company was established in 2007 as a spin-off from the Cancer Center Karolinska at Karolinska Institutet in Stockholm. This research has resulted in the development of the Prostatype® Test System, an IVDR-approved product that is commercially available today. In addition to the European market, Prostatype® has also been introduced in the United States, where the test is used clinically. All necessary regulatory and commercial prerequisites for the U.S. market are therefore already in place.

Prostatype® is a patented genetic test used to assess the prognosis of prostate cancer and provide additional decision support when selecting a treatment strategy. The test analyses gene expression in the patient's prostate biopsy, with a particular focus on genes associated with embryonic cancer stem cells. Since the analysis is performed on tissue samples already collected as part of the diagnostic process, no additional sampling is required. This contributes both to a smoother patient journey and to a more precise basis for treatment decisions.

The test is designed to complement the diagnostic and prognostic methods currently used in routine healthcare. In the Board of Directors' assessment, Prostatype® is the only patented prostate cancer test that focuses on gene expression associated with embryonic cancer stem cells while also being designed to be performed by independent hospitals and laboratories.

By analyzing gene activity in prostate cancer cells, combined with advanced algorithms and extensive data processing, Prostatype® generates decision support for personalized treatment of patients diagnosed with prostate cancer. Using artificial intelligence, the test can provide a more accurate prognostic assessment and classify patients according to different risk levels. This may reduce the risk of both overtreatment and undertreatment, potentially helping to limit serious and long-term side effects such as erectile dysfunction and incontinence.

The Prostatype® Test System consists of several integrated components: the Prostatype® RT-qPCR Kit, patient databases and analytical algorithms, the web-based PWS (Prostatype Web System), and the associated risk indicator, the P-score.

Prostatype Genomics has initiated the commercialization of Prostatype® and is pursuing a focused strategy aimed at maximizing market penetration in selected markets in the most cost-effective manner, with the objective of generating recurring sales revenues and demonstrating the business model across different geographic markets. In addition to focused sales efforts, an important part of the strategy is to further strengthen the scientific foundation through local validation studies, which are often a prerequisite for physicians and healthcare providers to adopt a new product. The United States is the Company's primary strategic focus, while operations are also conducted in selected EMEA markets, including the Nordic region, with a focus on Sweden, Spain and Italy.

Over the past several years, the Company has systematically worked to map and evaluate different markets and commercial approaches in individual countries, with the aim of determining whether the following criteria are met or can be met in the near term:

- clinical acceptance of genetic testing in prostate cancer and confirmed clinical utility; and
- market acceptance, demonstrated by clinics evaluating and beginning to use Prostatype®.

THE OFFERING IN BRIEF

Exercise period: 1-15 September 2026.

Exercise price: SEK 0.10 per share.

Issue volume: upon full exercise of the warrants of series TO6, the Company will receive approximately SEK 12.5 million before transaction related costs.

Subscription commitments, top-down underwriting commitment and letters of intent: ahead of the exercise of the warrants, the Company has received subscription commitments, a top-down underwriting commitment and letters of intent corresponding to a total of approximately SEK 8.7 million (approximately 70 percent). The underwriting commitment carries a fee of 2 percent in cash and 10 percent in shares, on the same terms and conditions as those applicable to TO6.

Last day of trading in TO6: 11 September 2026.

Please note that your bank or nominee for administrative reasons may assume a day of exercise that is ahead of 15 September 2026. For questions regarding your specific deadline, please contact your bank/nominee.

SUMMARIZED TERMS FOR TO6

SUMMARIZED TERMS FOR TO6
There are 125,225,546 outstanding warrants of series TO6. Holders of warrants of series TO6 have the right to, for each warrant, subscribe for one (1) new share in Prostatype Genomics AB at a price of SEK 0.10 per share.

Subscription with support of warrants of series TO6 takes place during the period from and including 1 September 2026 up to and including 15 September 2026. Subscription shall be made by simultaneous cash payment no later than 3:00 p.m. on 15 September 2026.

AS A WARRANT HOLDER, YOU NEED TO DECIDE WHETHER TO ACCEPT THE OFFER – THIS IS HOW TO EXERCISE YOUR SERIES TO6 WARRANTS
To ensure that your warrants do not expire worthless, you must subscribe for new shares by exercising your warrants no later than 3:00 p.m. on 15 September 2026, or alternatively sell your warrants no later than 11 September 2026. The ISIN code for TO6 is SE0029529767.

Your warrants may be registered in one of two ways:

1. In a securities account with a bank or other custodian (such as Avanza or Nordnet), in an investment savings account (ISK), or in an endowment insurance account (KF). In this case, your warrants are nominee-registered.
2. In a VP account (a VP account starts with three zeros and consists of a total of 12 digits). In this case, your warrants are directly registered.

Subscription for and payment of new shares through the exercise of warrants must be made through the bank or other custodian with which the warrants are registered. Subscription and payment must be made in accordance with the instructions provided by each such bank or custodian. Banks/custodians usually send a digital notification to the account holder. Otherwise, it is generally sufficient to log in to your securities account from the first day of the exercise period to access instructions on how to exercise the warrants to subscribe for new shares. Please contact your bank or custodian if you cannot find these instructions.

Please note that banks and other custodians may set different deadlines for subscription. You are therefore advised to contact your bank/custodian early during the exercise period to obtain information regarding subscription and payment. Shares that have been subscribed for and paid for may be registered in your securities account as "interim shares" or "IA" until the issue has been registered with the Swedish Companies Registration Office (Bolagsverket), at which point the interim shares will automatically be converted into ordinary shares in Prostatype Genomics AB.

DIRECTLY REGISTERED TO6
No issue statement will be sent out. Subscription for new shares through the exercise of warrants must be made by submitting a fully completed subscription form to Vator Securities AB by email. Payment must be made in accordance with the payment instructions provided on the subscription form at the same time as the subscription form is submitted to Vator Securities AB. The subscription form and this information document are available on the Company's website (www.prostatypegenomics.com) and Vator Securities AB's website (www.vatorsecurities.se).

The completed subscription form and payment must be received by Vator Securities AB no later than 3:00 p.m. on 15 September 2026. Shares that have been subscribed for and paid for will be registered in your VP account as "interim shares" or "IA" until the issue has been registered with the Swedish Companies Registration Office (Bolagsverket), at which point the interim shares will automatically be converted into ordinary shares in Prostatype Genomics AB.

SUBSCRIPTION OVER EUR 15,000 IF APPLICABLE
If your subscription amounts to or exceeds EUR 15,000, an anti-money laundering form must be completed and submitted to Vator Securities AB in accordance with the Swedish Act (2017:630) on Measures against Money Laundering and Terrorist Financing, at the same time as payment is made. Please note that interim shares cannot be delivered to your account, even if payment has been received, until the anti-money laundering documentation has been received by Vator Securities AB. The anti-money laundering form can be obtained from Vator Securities AB.

IMPORTANT DATES FOR WARRANTS OF SERIES TO6
- 1 September 2026 – exercise period starts
- 11 September 2026 – last day of trading in warrants
- 15 September 2026 – exercise period ends
- 16 September 2026 – planned date for publication of outcome of warrant exercise
- Around 1 October 2026 – planned date for change of interim shares to ordinary shares

PLEASE NOTE – To ensure that your warrants do not expire worthless, you must actively subscribe for and pay for shares no later than 3:00 p.m. CEST on 15 September 2026, or alternatively sell your warrants no later than 11 September 2026. If you have any questions regarding the Series TO6 warrants, please contact Navia Corporate Finance AB, Birchtree Advisory AB or Vator Securities AB.

Navia Corporate Finance AB and Birchtree Advisory AB are acting as financial advisors to Prostatype Genomics in connection with the exercise of the warrants. Vator Securities AB is acting as issuing agent, and Advokatfirman Lindahl is acting as legal advisor.

For further information about the Company and the risks associated with an investment, please see the information memorandum published by the Company on July 8, 2026. Full terms and conditions and instructions for TO6 are available on the Company's website.

Navia Corporate Finance AB
E-mail: info@naviacf.se

Birchtree Advisory AB
E-mail: jonas.bjorkman@birchtreeadvisory.se

Vator Securities AB
E-mail: emissioner@vatorsec.se

Prostatype Genomics